During the recent session, Gilead Sciences, Inc (NASDAQ:GILD)’s traded shares were 2.15 million, with the beta value of the company hitting 0.31. At the last check today, the stock’s price was $96.49, reflecting an intraday loss of -2.44% or -$2.41. The 52-week high for the GILD share is $119.96, that puts it down -24.32 from that peak though still a striking 35.67% gain since the share price plummeted to a 52-week low of $62.07. The company’s market capitalization is $120.29B, and the average trade volume was 9.73 million shares over the past three months.
Gilead Sciences, Inc (GILD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.84. GILD has a Sell rating from 0 analyst(s) out of 17 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.95.
Gilead Sciences, Inc (NASDAQ:GILD) trade information
Gilead Sciences, Inc (GILD) registered a -2.44% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.44% in intraday trading to $96.49, hitting a weekly high. The stock’s 5-day price performance is -6.55%, and it has moved by -6.49% in 30 days. Based on these gigs, the overall price performance for the year is 47.22%.
The consensus price target of analysts on Wall Street is $126, which implies an increase of 23.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $83 and $132 respectively. As a result, GILD is trading at a discount of -36.8% off the target high and 13.98% off the low.
Gilead Sciences, Inc (GILD) estimates and forecasts
In the rating firms’ projections, revenue will decrease -0.35% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.95B as predicted by 19 analyst(s). Meanwhile, a consensus of 18 analyst(s) estimates revenue growth to 7.39B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 6.95B and 7.54B respectively.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.13%. While earnings are projected to return 73.01% in 2025, the next five years will return 25.74% per annum.
GILD Dividends
Gilead Sciences, Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Gilead Sciences, Inc is 3.10, with the dividend yield indicating at 3.21 percent, continuing the trend of increasing dividends in recent years.
The next largest institutional holding, with 115.26 million shares, is of VANGUARD GROUP INC’s that is approximately 9.2431% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.91 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Gilead Sciences, Inc (GILD) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 39.06 shares. This amounts to just over 3.14 percent of the company’s overall shares, with a $3.8 billion market value. The same data shows that the other fund manager holds slightly less at 33.73, or about 2.71% of the stock, which is worth about $3.28 billion.
